OMEROS CORPORATION (NASDAQ:OMER) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

OMEROS CORP Exhibit
EX-99.1 2 d441790dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721 – Sustained Proteinuria Reduction and GFR Improvement in up to One-Year Follow-up Data – SEATTLE,…
To view the full exhibit click here

About OMEROS CORPORATION (NASDAQ:OMER)

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.